MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it has enrolled the first patient to its ZAM App in the UK, allowing it to collect data from an observational study monitoring the effects of the company's epilepsy treatment, CannEpil.
The technology will record daily metrics from patients, their symptoms, and the impact of their treatment in order to establish a baseline.
This will then provide doctors and MGC with a detailed record of the study and an enhanced understanding of the effect of CannEpil on Refractory Epilepsy patients.
In addition to prompting patients with medication reminders, the app will also measure treatment progress and allow for a qualified doctor to prescribe alternative medication following a consultation.
The trial is supported by the I am Billy Foundation, which helps parents and families obtain NHS-funded Medical Cannabis for children.
In a statement, MGC’s managing director, Roby Zomer, said: "The enrolment of the first patient in the ZAM App in the UK enables us to fully record the impact and efficacy of our products undergoing trials.
“Consolidation of data is of paramount importance in ensuring the safety and efficiency of MGC's proprietary products, and we see the integration of both pharma and tech as a revolution in the clinical trial process."
MGC specialises in the development of plant-based treatments for unmet conditions.